Promedior Inc., a privately held clinical-stage biotechnology company based in Lexington, Massachusetts, has agreed to be acquired by Roche (RHHBY) in a deal with total transaction value of up to $1.39 billion. Roche will make an upfront cash payment of $390 million, plus additional contingent payments of up to $1 billion.
With the acquisition, Roche will obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, including PRM-151. Promedior has successfully advanced PRM-151 in human clinical trials and received Breakthrough Therapy Designation from the FDA earlier in the current year for idiopathic pulmonary fibrosis.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.